Quantcast
Environmental News for a Healthier Planet and Life

FDA Approves Ebola Vaccine

Health + Wellness
FDA Approves Ebola Vaccine

Ebola virus seen under a microscope. Studio_3321 / iStock / Getty Images Plus

The U.S. Food and Drug Administration (FDA) announced Thursday that it has approved a vaccine for Ebola manufactured by Merck, according to Reuters.


Merck's vaccine, Ervebo, was also approved by the European Commission in November, as STAT reported.

The vaccine was used widely by the World Health Organization and the Democratic Republic of Congo to help reduce the spread of the Ebola virus in a few West African countries from 2014 to 2016, according to Reuters. Ebola Zaire is the strain of the virus responsible for the ongoing outbreak in the Democratic Republic of the Congo, according to STAT.

The Ebola virus is extremely rare in the U.S. The only cases that have ever existed are from people infected in other countries who traveled to the U.S. or from healthcare workers who treated people infected with the virus, according to ABC News.

"Ebola virus disease is a rare but severe and often deadly disease that knows no borders," said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, in a statement reported by STAT. "Vaccination is essential to help prevent outbreaks and to stop the Ebola virus from spreading when outbreaks do occur."

Secretary of Health and Human Services Alex Azar touted the vaccine, which is a single-dose injection that works within 10 days of injection, as "a triumph of American global health leadership," according to CNN.

The Ebola Zaire virus has claimed thousands of life in West Africa and set off widespread panic during an outbreak in 2014. The current outbreak has claimed 2,000 lives in the Democratic Republic of Congo, while the outbreak in 2014 led to more than 11,000 deaths in West Africa, according to CNN.

The Ebola virus causes hemorrhagic fever, which can quickly shut down bodily functions. It spreads when a person makes direct contact with the bodily fluids of an infected person, as ABC News reported.

The vaccine is approved for patients 18 and older. It will make up a large portion of the vaccine stockpile held by the Gavi, the Vaccine Alliance, to have readily available at the next sign of an outbreak, according to STAT. Gavi recently said it planned to stockpile half a million doses of the vaccine. Ervebo is attractive to Gavi for its simplicity since it is just a single-dose and has a fairly quick immune response time of just 10 days, as STAT reported.

"While the risk of Ebola virus disease in the U.S. remains low, the U.S. government remains deeply committed to fighting devastating Ebola outbreaks in Africa, including the current outbreak in the Democratic Republic of the Congo," said Anna Abram, FDA deputy commissioner for policy, legislation and international affairs, in a statement Thursday, as ABC News reported. "Today's approval is an important step in our continuing efforts to fight Ebola in close coordination with our partners across the U.S. Department of Health and Human Services, as well as our international partners, such as the World Health Organization."

The vaccine has been in the works for decades, starting in the 90s. However, the dearth of commercial interest in an Ebola vaccine kept large pharmaceutical companies from partnering in the research and development of the drug. The outbreak in 2014 triggered a change in attitude and the drug was rapidly developed.

It underwent extensive testing, culminating in a clinical trail in Guinea, which was effected by the outbreak. Ervebo proved effective in stopping the spread of the virus, as STAT reported.

More than 258,000 people have been vaccinated in the current outbreak, according to STAT.

martin-dm / E+ / Getty Images

By Jason Farley

COVID-19 has disrupted our daily lives, and it is poised to completely disrupt the holiday season. As people make holiday plans and think about ways to reduce the risks to their loved ones, a strategy is essential.

Read More Show Less

EcoWatch Daily Newsletter

Key West voters have passed three ballot initiatives to limit the impact of visiting cruise ships on island life and fragile marine habitats. felixmizioznikov / iStock / Getty Images Plus

Despite being a well-known port of call on the Caribbean cruise circuit, the City of Key West voted to ban large cruise ships from visiting and to restrict foot traffic from vessels. Supporters and opponents disagreed about the safety, environmental and economic merits of the proposals.

Read More Show Less

Trending

Wind turbines are seen in Palm Springs, California. Mint Images / Getty Images

By Tara Lohan

How much of U.S. energy demand could be met by renewable sources?

According to a new report from the Institute for Local Self-Reliance, the answer is an easy 100%.

Read More Show Less
A team of scientists found microplastics in every snow sample taken from Mount Everest. Mariusz Potocki / National Geographic

Apparently, there ain't no mountain high enough to keep away the twin pressures of plastic pollution and the climate crisis.

Read More Show Less
A woman is seen shopping in a boutique. Thomas Barwick / Getty Images

By Amol Mehra

Set against rising calls for action to combat growing inequality and the climate crisis, the COVID-19 pandemic underscores the importance of the key drivers of industry and economic reform: workers, communities and the environment.

Read More Show Less